Skip to main content
Granules India Ltd. logo

Granules India Ltd. — Investor Relations & Filings

Ticker · GRANULES ISIN · INE101D01020 LEI · 335800HJF1KE335ASX37 BSE.NS Manufacturing
Open in API
Filings indexed 960 across all filing types
Latest filing 2026-06-03 Regulatory Filings
Country IN India
Listing BSE.NS GRANULES

About Granules India Ltd.

https://granulesindia.com/

Granules India Ltd. is a vertically integrated manufacturer specializing in Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). The organization maintains a significant global presence through the large-scale production of essential molecules, including Paracetamol, Ibuprofen, Metformin, Methocarbamol, and Guaifenesin. Its business model emphasizes a complete value chain approach, from core chemical synthesis to final product packaging, ensuring operational efficiency and supply chain security. The company serves a diverse international clientele across more than 75 countries, utilizing advanced manufacturing facilities that comply with global regulatory standards. Key strengths include high-volume production capabilities, cost leadership, and a focus on delivering consistent quality in high-demand therapeutic areas.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 82% confidence The document is a press release filed with the stock exchanges (NSE & BSE) announcing receipt of the FDA Establishment Inspection Report (EIR) for its Chantilly facility. It is a routine regulatory announcement to disseminate corporate information, not a financial report (10-K, IR), earnings release, or proxy-related filing. It does not contain financial statements or management discussion of results. Therefore, it falls under the general regulatory announcements category (RNS).
2026-06-03 English
Press Release
Regulatory Filings Classification · 85% confidence The document is a press release filed with the National Stock Exchange of India and BSE, announcing that the company’s US subsidiary received an Establishment Inspection Report (EIR) from the US FDA. It does not contain financial statements or results, nor is it an annual/interim report, earnings release, management change, share issuance, or M&A filing. It is a general regulatory announcement and thus falls under the fallback category for miscellaneous regulatory filings.
2026-06-03 English
Clarification on Volume Movement sought by the Exchanege
Regulatory Filings Classification · 85% confidence The document is a formal letter to the stock exchange (BSE) clarifying a regulatory query about a volume movement of the company’s security. It cites SEBI Listing Regulations, 2015 and confirms compliance with Regulation 30 disclosures. It is not an earnings release, share issue, management change, or any detailed financial report; rather, it is a routine compliance/ regulatory announcement. This fits the “Regulatory Filings” (RNS) category for general exchange disclosures and compliance documents.
2026-05-29 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 90% confidence The document is a brief SEBI (Listing Obligations and Disclosure Requirements) Regulation 30 intimation to stock exchanges about a scheduled analyst/investor meeting. It does not contain actual financial results, presentation slides, or transcripts, but is a compliance announcement. This fits the catch-all category for regulatory announcements and disclosures (RNS).
2026-05-28 English
Schedule of Analyst & Investor Meet
Regulatory Filings Classification · 85% confidence The document is a short SEBI Regulation 30 intimation to exchanges about the schedule for management meetings with analysts/investors. It contains no financial data or presentation materials, but is a regulatory announcement of an investor/analyst meet. It does not fit other specific categories, so it falls under general regulatory filings (RNS).
2026-05-28 English
Spurt in Volume
Regulatory Filings Classification · 90% confidence The document is a short compliance letter addressed to the National Stock Exchange regarding a regulatory query on unusual trading volume. It references SEBI Listing Regulations and provides clarifications. It does not contain financial statements, management discussion, or constitute an earnings or annual report, nor does it announce dividends, board changes, capital transactions, or merger activity. It is a regulatory disclosure/filing under Listing Obligations, fitting the “Regulatory Filings” (RNS) category.
2026-05-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.